Published in Biochem Biophys Res Commun on February 21, 1969
In vitro polyoma DNA synthesis: inhibition by 1-beta-d-arabinofuranosyl CTP. J Virol (1975) 57.17
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res (2012) 1.20
DNA synthesis involving a complexes form of DNA polymerase I in extracts of Escherichia coli. Proc Natl Acad Sci U S A (1975) 1.06
Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest (1979) 0.80
Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro. Proc Natl Acad Sci U S A (1981) 0.79
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70
A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res (1974) 1.48
Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol (1983) 1.37
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol (1983) 1.24
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res (1983) 1.19
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol (1993) 1.15
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res (1981) 1.15
Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther (1985) 1.08
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther (1985) 1.07
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol (1992) 1.07
Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem (1968) 1.06
In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res (1977) 1.04
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res (1984) 1.04
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol (2001) 1.03
Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res (1983) 1.03
Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol (1972) 1.03
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs (1999) 1.01
Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta (1968) 1.01
Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs (1998) 1.00
Mammalian deoxynucleoside kinases. II. Deoxyadenosine kinase: purification and properties. J Biol Chem (1971) 0.99
Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol (1979) 0.97
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res (1985) 0.97
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (1984) 0.95
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. J Pharm Sci (1981) 0.94
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol (1998) 0.93
Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res (1994) 0.90
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 0.86
Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res (1974) 0.85
Sample preparation for the determination of 5-aza-2'-deoxycytidine in plasma by high-performance liquid chromatography. J Chromatogr (1985) 0.83
Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res (1986) 0.83
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia. Cancer Treat Rep (1984) 0.83
Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol Pharmacol (1971) 0.83
Effect of DNA polymerase on nuclei from different phases of cell cycle. Eur J Biochem (1974) 0.82
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther (2001) 0.81
Mammalian deoxynucleoside kinases. IV. Deoxythymidine kinase: purification, properties, and kinetic studies. J Biol Chem (1971) 0.81
Mammalian deoxynucleoside kinases. 3. Deoxyadenosine kinase: inhibition by nucleotides and kinetic studies. J Biol Chem (1971) 0.81
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res (1995) 0.81
Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J Viral Hepat (2006) 0.80
Toxicology in mice of the antileukemic agent 5-aza-2'-deoxycytidine. Drug Chem Toxicol (1981) 0.80
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res (1984) 0.80
Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. Leuk Res (1993) 0.80
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs (1991) 0.80
Effect of tRNA from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system. Biochem Pharmacol (1976) 0.79
Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase. Mol Pharmacol (1984) 0.79
Inhibition of cytotoxic action of 1- -D-arabinofuranosylcytosine on S-phase HeLa cells by 5-fluorodeoxyuridine. Cancer Res (1973) 0.79
Increased sensitivity to a vitamin D3 analog in HL-60 myeloid leukemic cells resistant to all-trans retinoic acid. Leukemia (1994) 0.79
Kinetic studies with 5-azacytidine-5'-triphosphate and DNA-dependent RNA polymerase. Biochem Pharmacol (1977) 0.79
The regulatory properties of deoxyadenosine kinase. Biochim Biophys Acta (1968) 0.79
Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. Leuk Res (1996) 0.78
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine. Semin Oncol (1987) 0.78
Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res (1979) 0.78
Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther (2002) 0.78
Enzymatic estimation and metabolism of 1- -D-arabinofuranosylcytosine in man. Cancer Res (1972) 0.78
Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells. Cancer Treat Rep (1984) 0.78
Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice. Gene Ther (1998) 0.78
In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination. Cancer Res (1975) 0.78
Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. Cancer Gene Ther (2000) 0.77
Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. Hum Gene Ther (1998) 0.77
Effect of 5-aza-2'-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. Cancer Chemother Pharmacol (1998) 0.77
Enzymatic synthesis of 5-azacytidine 5'-triphosphate from 5-azacytidine. Anal Biochem (1976) 0.77
Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2'-deoxycytidine in tumor cells using a single-nucleotide primer extension assay. Anal Biochem (2000) 0.77
Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells. Anticancer Drugs (1994) 0.76
5-Aza-2'-deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells. Cell Differ Dev (1989) 0.76
Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Anticancer Drugs (1993) 0.76
Biochemical pharmacology of cytosine arabinoside. Med Pediatr Oncol (1982) 0.76
Studies on analogs of isosteric and allosteric ligands of deoxycytidylate aminohydrolase. Biochemistry (1970) 0.75
Gene amplification of human cytidine deaminase proviral cDNA and increased levels of its mRNA produces enhanced drug resistance to cytosine arabinoside in retroviral-transduced murine fibroblasts. Cancer Lett (1999) 0.75
Effects of trimethoprim on leukaemic cells in vitro. Br J Haematol (1981) 0.75
Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine. Int J Cancer (1982) 0.75
Potential of ribozymes against deoxycytidine kinase to confer drug resistance to cytosine nucleoside analogs. Biochem Biophys Res Commun (2000) 0.75
5-AZA-2'-deoxycytidine synergistic action with thymidine on leukemic cells and interaction of 5-AZA-dCMP with dCMP deaminase. Adv Exp Med Biol (1986) 0.75
Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy. Semin Oncol (1985) 0.75
Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells. Anticancer Drugs (1992) 0.75
Relationship of nutritional factors to in vitro tumor cell growth and cytotoxicity produced by cytosine arabinoside. Cell Tissue Kinet (1977) 0.75
Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene. Prog Exp Tumor Res (1999) 0.75
[In vitro test for studying sensitivity to Ara-C in leukemic patients]. Union Med Can (1987) 0.75
Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography. Ther Drug Monit (1983) 0.75